Humanized and chimeric antibodies specific for lipoteichoic acid of GRAM positive bacteria
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12P-021/08
C07K-016/00
A61K-039/395
G01N-033/574
C12P-021/04
C07H-021/04
C07H-021/00
출원번호
US-0193440
(2005-08-01)
등록번호
US-7511122
(2009-03-31)
발명자
/ 주소
Fischer,Gerald Walter
Schuman,Richard F.
Wong,Hing
Stinson,Jeffrey R.
출원인 / 주소
Henry M. Jackson Foundation for the Advancement of Military Medicine
Altor BioScience Corporation
대리인 / 주소
Lahive & Cockfield, LLP
인용정보
피인용 횟수 :
0인용 특허 :
40
초록▼
The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse mono
The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.
대표청구항▼
We claim: 1. A humanized antibody or an antigen-binding fragment thereof having binding specificity to LTA of Gram positive bacteria, the humanized antibody comprising: (i) a light chain comprising three complementarity determining regions (CDRs) from the immunoglobulin light chain variable region
We claim: 1. A humanized antibody or an antigen-binding fragment thereof having binding specificity to LTA of Gram positive bacteria, the humanized antibody comprising: (i) a light chain comprising three complementarity determining regions (CDRs) from the immunoglobulin light chain variable region sequence set forth as SEQ ID NO:89, and framework regions from a human acceptor immunoglobulin light chain; and (ii) a heavy chain comprising three complementarity determining regions (CDRs) from the immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO:87, and framework regions from a human acceptor immunoglobulin heavy chain. 2. The humanized antibody of claim 1, which enhances opsonization of Gram-positive bacteria over background as compared to an appropriate control in an in vitro opsonization assay. 3. The humanized antibody of claim 2, wherein the opsonization assay is performed in the presence of complement, cells, a cell line, or a combination thereof. 4. The humanized antibody of claim 3, wherein the complement or cells or both are human in origin. 5. The humanized antibody of claim 3, wherein the cells are phagocytic cells. 6. The humanized antibody of claim 3, wherein the cells are macrophages, monocytes, neutrophils, or combinations thereof. 7. The humanized antibody of claim 3, wherein the opsonization is measured by measuring opsonophagocytic bactericidal activity. 8. The humanized antibody or antigen-binding fragment thereof of claim 1, wherein the antibody binds LTA of Gram positive bacteria fixed to a solid support. 9. The humanized antibody or antigen-binding fragment thereof of claim 8, wherein the solid support is a plate well, bead, or a micro-bead. 10. The humanized antibody of claim 1, which confers a statistically significant enhancement of survival or reduced bacteremia in an animal model. 11. The humanized antibody of claim 10, wherein the statistically significant enhancement of survival in an animal model is 25% or greater. 12. The humanized antibody of claim 10, wherein the statistically significant enhancement of survival in an animal model is 50% or greater. 13. The humanized antibody of claim 10, wherein the statistically significant enhancement of survival in an animal model is 70% or greater. 14. The humanized antibody of claim 10, wherein the statistically significant enhancement of survival in an animal model is 76% or greater. 15. The humanized antibody of claim 10, wherein the statistically significant enhancement of survival in an animal model is 90% or greater. 16. The humanized antibody of claim 10, wherein the statistically significant enhancement of survival in an animal model is between 67% and 83%. 17. The humanized antibody of claim 10, wherein the statistically significant enhancement of survival in an animal model is between 83% and 100%. 18. The humanized antibody or antigen-binding fragment thereof of claim 1, which binds to LTA at a level that is twice background or greater. 19. The humanized antibody or antigen-binding fragment thereof of claim 1, which recognizes a peptide sequence selected from: WRMYFSHRHAHLRSP (SEQ ID NO 1); and WHWRHRIPLQLAAGR (SEQ ID NO 2). 20. The humanized antibody of claim 1, further comprising human constant regions of an IgG isotype or an IgM isotype. 21. The humanized antibody or antigen-binding fragment thereof of claim 1, which is an antigen-binding fragment selected from the group consisting of Fab, Fab', F(ab')2, or SFv. 22. The humanized antibody of claim 1, which enhances survival in an animal model by 10% or more over animals not treated with the humanized antibody. 23. A composition comprising the humanized antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier. 24. The humanized antibody or antigen-binding fragment thereof of any claim 1, further comprising an amino acid substitution in the framework regions. 25. The humanized antibody or antigen-binding fragment thereof of claim 1, which is a humanized antibody which blocks the binding of gram positive bacteria to human epithelial cells. 26. The humanized antibody of claim 2, wherein the opsonization is measured by measuring opsonophagocytic activity. 27. A chimeric antibody comprising the heavy chain variable region sequence set forth as SEQ ID NO:87 and the light chain variable region sequence set forth as SEQ ID NO:89 and human constant regions. 28. The chimeric antibody of claim 27, which enhances opsonization of Gram-positive bacteria over background as compared to an appropriate control in an in vitro opsonization assay. 29. The chimeric antibody of claim 28, wherein the opsonization assay is performed in the presence of complement, cells, a cell line, or a combination thereof. 30. The chimeric antibody of claim 29, wherein the complement or cells or both are human in origin. 31. The chimeric antibody of claim 29, wherein the cells are phagocytic cells. 32. The chimeric antibody of claim 29, wherein the cells are macrophages, monocytes, neutrophils, or combinations thereof. 33. The chimeric antibody of claim 29, wherein opsonization is measured by measuring opsonophagocytic activity. 34. The chimeric antibody of claim 29, wherein opsonization is measured by measuring opsonophagocytic bactericidal activity. 35. The chimeric antibody of claim 27, wherein the antibody is capable of binding to LTA of Gram positive bacteria fixed to a solid support. 36. The chimeric antibody of claim 35, wherein the solid support is a plate well, bead, or a micro-bead. 37. The chimeric antibody of claim 27, which confers a statistically significant enhancement of survival or reduced bacteremia in an animal model. 38. The chimeric antibody of claim 37, wherein the statistically significant enhancement of survival in an animal model is 25% or greater. 39. The chimeric antibody of claim 37, wherein the statistically significant enhancement of survival in an animal model is 50% or greater. 40. The chimeric antibody of claim 37, wherein the statistically significant enhancement of survival in an animal model is 70% or greater. 41. The chimeric antibody of claim 37, wherein the statistically significant enhancement of survival in an animal model is 76% or greater. 42. The chimeric antibody of claim 37, wherein the statistically significant enhancement of survival in an animal model is 90% or greater. 43. The chimeric antibody of claim 37, wherein the statistically significant enhancement of survival in an animal model is between 67% and 83%. 44. The chimeric antibody of claim 37, wherein the statistically significant enhancement of survival in an animal model is between 83% and 100%. 45. The chimeric antibody of claim 27, which binds to LTA at a level that is twice background or greater. 46. The chimeric antibody of claim 27, which recognizes a peptide sequence selected from: WRMYFSHRHAHLRSP (SEQ ID NO 1); and WHWRHRIPLQLAAGR (SEQ ID NO 2). 47. The chimeric antibody of claim 27, in which the human constant region is of the IgG isotype or IgM isotype. 48. The chimeric antibody of claim 27, which enhances survival in an animal model by 10% or more over animals not treated with the chimeric antibody. 49. A composition comprising the chimeric antibody of claim 27 and a pharmaceutically acceptable carrier. 50. The chimeric antibody of claim 27, wherein the chimeric antibody blocks the binding of Gram positive bacteria to human epithelial cells. 51. A humanized antibody or an antigen-binding fragment thereof having binding specificity to LTA of Gram positive bacteria, the humanized antibody comprising: (i) a light chain comprising three complementarity determining regions (CDRs) from the immunoglobulin light chain variable region sequence set forth as SEQ ID NO:89; and (ii) a heavy chain comprising three complementarity determining regions (CDRs) from the immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO:87. 52. The humanized antibody of claim 51 further comprising human constant regions of an IgG isotype or IgM isotype. 53. The humanized antibody or antigen-binding fragment thereof of 51, which is an antigen-binding fragment selected from the group consisting of Fab, Fab', F(ab')2, or SFv. 54. A composition comprising the humanized antibody or antigen-binding fragment thereof of claim 51 and a pharmaceutically acceptable carrier. 55. The humanized antibody or antigen-binding fragment thereof of claim 51, wherein the humanized antibody blocks the binding of Gram positive bacteria to human epithelial cells. 56. A chimeric antibody comprising the heavy chain variable region sequence set forth as SEQ ID NO:87 and the light chain variable region sequence set forth as SEQ ID NO:90 and human constant regions. 57. The chimeric antibody of claim 56 which enhances opsonization of Gram-positive bacteria over background as compared to an appropriate control in an in vitro opsonization assay. 58. The chimeric antibody of claim 57, wherein the opsonization assay is performed in the presence of complement, cells, a cell line, or a combination thereof. 59. The chimeric antibody of claim 58, wherein the complement or cells or both are human in origin. 60. The chimeric antibody of claim 58, wherein the cells are phagocytic cells. 61. The chimeric antibody of claim 58, wherein the cells are macrophages, monocytes, neutrophils, or combinations thereof. 62. The chimeric antibody of claim 58, wherein opsonization is measured by measuring opsonophagocytic activity. 63. The chimeric antibody of claim 58, wherein opsonization is measured by measuring opsonophagocytic bactericidal activity. 64. The chimeric antibody of claim 56, wherein the antibody is capable of binding to LTA of Gram positive bacteria fixed to a solid support. 65. The chimeric antibody of claim 64, wherein the solid support is a plate well, bead, or a micro-bead. 66. The chimeric antibody of claim 56, which confers a statistically significant enhancement of survival or reduced bacteremia in an animal model. 67. The chimeric antibody of claim 66, wherein the statistically significant enhancement of survival in an animal model is 25% or greater. 68. The chimeric antibody of claim 66, wherein the statistically significant enhancement of survival in an animal model is 50% or greater. 69. The chimeric antibody of claim 66, wherein the statistically significant enhancement of survival in an animal model is 70% or greater. 70. The chimeric antibody of claim 66, wherein the statistically significant enhancement of survival in an animal model is 76% or greater. 71. The chimeric antibody of claim 66, wherein the statistically significant enhancement of survival in an animal model is 90% or greater. 72. The chimeric antibody of claim 66, wherein the statistically significant enhancement of survival in an animal model is between 67% and 83%. 73. The chimeric antibody of claim 66, wherein the statistically significant enhancement of survival in an animal model is between 83% and 100%. 74. The chimeric antibody of claim 56, which binds to LTA at a level that is twice background or greater. 75. The chimeric antibody of claim 56, which recognizes a peptide sequence selected from: WRMYFSHRHAHLRSP (SEQ ID NO 1); and WHWRHRIPLQLAAGR (SEQ ID NO 2). 76. The chimeric antibody of claim 56, in which the human constant region is of the IgG isotype or IgM isotype. 77. The chimeric antibody of claim 56, which enhances survival in an animal model by 10% or more over animals not treated with the chimeric antibody. 78. A composition comprising the chimeric antibody of claim 56 and a pharmaceutically acceptable carrier. 79. The chimeric antibody of claim 56, wherein the chimeric antibody blocks the binding of Gram positive bacteria to human epithelial cells.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (40)
Kiselev Anatoly Efimovich (ULITSA Kostyakova ; 8/6 ; kv. 182 Moscow SU) Skurkovich Semen Vladimirovich (Frunzensky val ; 38 ; kv. 103 Moscow SU) Golosova Tatyana Vasilievna (ULITSA B. Gruzinskaya ; 6, Antistaphylococcous human immunoglobulin and method of preparing same.
Frank Robert (Strasbourg FRX) Klein Jean P. (Breuschwickersheim FRX) Ackermans Fabienne (Brussels BEX) Bazin Herv (Brussels BEX), Conjugate constituted from a wall adhesin of S. mutans of proteinic nature and from a polysaccharide of 상세보기
Carroll Sean B. (Cottage Grove WI) Firca Joseph R. (Vernon Hills IL) Pugh Charles (Madison WI) Padhye Nisha V. (Madison WI), Conjugates for the prevention and treatment of sepsis.
Marburg Stephen (Metuchen NJ) Tolman Richard L. (Warren NJ) Jorn Deborah A. (Metuchen NJ), Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogeni.
Hk Magnus (Birmingham AL) Jnsson Klas (Studentvgen SEX) Lindberg Kjell M. (Kornvgen SEX) Signs Christer (Hamnesplanaden SEX), DNA encoding a fibronectin binding protein as well as its preparation.
Burnham Martin Karl Russel,GBX ; Chopra Ian,GBX ; Critchley Ian Alfred,GBX ; Knowles David Justin Charles,GBX, Fibronectin binding protein polypeptides.
Hunter Kenneth W. (4401 Dresden St. Kensington MD 20895) Fischer Gerald W. (10748 Wayridge Dr. Gaithersburg MD 20879), Human monoclonal antibody reactive with polyribosylribitol phosphate.
Gristina Anthony G. (Reston VA) Myrvik Quentin N. (Caswell Beach NC), Method and compositions for the direct concentrated delivery of passive immunity.
Emery Daryll A. (Willmar MN) Straub Darren E. (Willmar MN) Huisinga Richard (Willmar MN), Method of priming an immune response in a one-day old animal.
Gristina Anthony G. (11605 Deer Forest Rd. Reston VA 22094) Myrvik Quentin N. (404 Palmetto Dr. Caswell Beach NC 28465), Methods and compositions for the direct concentrated delivery of passive immunity.
Shockman Gerald D. (Philadelphia PA) Jackson Dianne E. (Brookline MA) Wong William (Wilmington DE), Monoclonal antibodies to peptidoglycan and methods of preparing same.
Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey R., Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria.
Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey R., Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria.
Fournier Jean-Michel (Paris FRX) Bouvet Anne (Paris FRX) Boutonnier Alain (Paris FRX), Process for the preparation of capsular polysaccharides of staphylococci, the polysaccharides obtained, uses of these po.
d\Hinterland Lucien D. (Castres FRX) Normier Grard (Castres FRX) Pinel Anne-Marie (Castres FRX) Durand Jacques (Castres FRX), Vaccinal complex containing a specific antigen and vaccine containing it.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.